Cargando…

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment

OBJECTIVES: To report the impact of continued burosumab treatment on clinical laboratory tests of efficacy, patient-reported outcomes (PROs) and ambulatory function in adults with X-linked hypophosphataemia who continued from a 96-week phase 3 study into a 48-week open-label extension. METHODS: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamenicky, Peter, Briot, Karine, Brandi, Maria Luisa, Cohen-Solal, Martine, Crowley, Rachel K, Keen, Richard, Kolta, Sami, Lachmann, Robin H, Lecoq, Anne-Lise, Ralston, Stuart H, Walsh, Jennifer S, Rylands, Angela J, Williams, Angela, Sun, Wei, Nixon, Annabel, Nixon, Mark, Javaid, Muhammad K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980374/ https://www.ncbi.nlm.nih.gov/pubmed/36854566 http://dx.doi.org/10.1136/rmdopen-2022-002676

Ejemplares similares

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
por: Seefried, Lothar, et al.
Publicado: (2023)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study
por: Padidela, Raja, et al.
Publicado: (2020)

SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
por: Haffner, Dieter, et al.
Publicado: (2019)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations
por: Padidela, Raja, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
por: Kubota, Takuo, et al.
Publicado: (2023)

Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction
por: Ifie, Eseoghene, et al.
Publicado: (2019)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

Validation of a next-generation sequencing (NGS) panel to improve the diagnosis of X-linked hypophosphataemia (XLH) and other genetic disorders of renal phosphate wasting
por: Thiele, Susanne, et al.
Publicado: (2020)

Clinical factors associated with severe hypophosphataemia after kidney transplant
por: Ralston, Maximilian R., et al.
Publicado: (2021)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial
por: Cohen-Solal, Alain, et al.
Publicado: (2009)

Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review
por: Seefried, L., et al.
Publicado: (2020)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

Severe hypophosphataemia after intravenous iron administration
por: Anand, Gurpreet, et al.
Publicado: (2017)

Isolated hypophosphataemia as an early marker of primary hyperparathyroidism
por: Alexander, John, et al.
Publicado: (2021)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

The ankle in XLH: Reduced motion, power and quality of life
por: Akta, Celine, et al.
Publicado: (2023)

Acute onset quadriparesis following oesophagectomy due to isolated hypophosphataemia
por: Naik, Vibhavari M, et al.
Publicado: (2019)

Life-threatening hypophosphataemia in a cirrhotic patient with jaundice
por: Moutzouri, Elisavet, et al.
Publicado: (2011)

Hypophosphataemia among Severely-malnourished Children: Case Series
por: Yoshimatsu, Shoji, et al.
Publicado: (2012)

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
por: Castellano-Martinez, Ana, et al.
Publicado: (2022)

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study
por: van der Togt, Céleste J T, et al.
Publicado: (2023)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Phenotypes of a family with XLH with a novel PHEX mutation
por: Yamamoto, Akiko, et al.
Publicado: (2020)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ulqo0cgpkn2e237m7pc8sqr4i6